| pubmed-article:9387877 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9387877 | lifeskim:mentions | umls-concept:C0025914 | lld:lifeskim |
| pubmed-article:9387877 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:9387877 | lifeskim:mentions | umls-concept:C1179435 | lld:lifeskim |
| pubmed-article:9387877 | lifeskim:mentions | umls-concept:C0017337 | lld:lifeskim |
| pubmed-article:9387877 | lifeskim:mentions | umls-concept:C0033413 | lld:lifeskim |
| pubmed-article:9387877 | lifeskim:mentions | umls-concept:C0054544 | lld:lifeskim |
| pubmed-article:9387877 | lifeskim:mentions | umls-concept:C0678594 | lld:lifeskim |
| pubmed-article:9387877 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:9387877 | pubmed:dateCreated | 1998-2-11 | lld:pubmed |
| pubmed-article:9387877 | pubmed:abstractText | The 5' flanking region of the mouse calretinin gene was cloned and a 1.8 kbp region adjacent to exon 1 was sequenced. Putative upstream promoter and enhancer elements were identified, including appropriately positioned TATA and CAAT boxes (positions -50 and -68, respectively). There was considerable sequence and structural homology between mouse and human upstream elements. Neuron-restrictive activity was demonstrated via transfection of calretinin promoter-reporter constructs into primary embryonic mouse brain cultures expressing calretinin. In promoterless reporter constructs, the proximal upstream 1.5 kbp of the mouse calretinin gene boosted luciferase activity (up to 100-fold) exclusively in the neuronal population. Deletion analysis revealed the minimal promoter to be within the 95-bp proximal to the transcription start site. Transfections with SV40 promoter constructs in these cultures resulted in reporter gene expression predominantly in non-neuronal cells. Inserting the proximal 1.5 kbp of mouse calretinin upstream in SV40 promoter-reporter constructs reduced luciferase activity. Thus, calretinin upstream sequences increased reporter expression in cultured neurons and decreased expression from the SV40 promoter in non-neuronal cultured brain cells. The calretinin promoter contained relevant regulatory element consensus motifs and demonstrated in vitro neuron-restrictive bioactivity. | lld:pubmed |
| pubmed-article:9387877 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9387877 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9387877 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9387877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9387877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9387877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9387877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9387877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9387877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9387877 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9387877 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:9387877 | pubmed:issn | 0169-328X | lld:pubmed |
| pubmed-article:9387877 | pubmed:author | pubmed-author:JacobowitzD... | lld:pubmed |
| pubmed-article:9387877 | pubmed:author | pubmed-author:HammerMM | lld:pubmed |
| pubmed-article:9387877 | pubmed:author | pubmed-author:Ku?nickiJJ | lld:pubmed |
| pubmed-article:9387877 | pubmed:author | pubmed-author:WinskyLL | lld:pubmed |
| pubmed-article:9387877 | pubmed:author | pubmed-author:StraussK IKI | lld:pubmed |
| pubmed-article:9387877 | pubmed:author | pubmed-author:KawagoeJ IJI | lld:pubmed |
| pubmed-article:9387877 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9387877 | pubmed:day | 3 | lld:pubmed |
| pubmed-article:9387877 | pubmed:volume | 49 | lld:pubmed |
| pubmed-article:9387877 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9387877 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9387877 | pubmed:pagination | 175-87 | lld:pubmed |
| pubmed-article:9387877 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:meshHeading | pubmed-meshheading:9387877-... | lld:pubmed |
| pubmed-article:9387877 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9387877 | pubmed:articleTitle | The mouse calretinin gene promoter region: structural and functional components. | lld:pubmed |
| pubmed-article:9387877 | pubmed:affiliation | NIMH, Laboratory of Clinical Science, Bethesda, MD 20892-1266, USA. kstrauss@thunder.ocis.temple.edu | lld:pubmed |
| pubmed-article:9387877 | pubmed:publicationType | Journal Article | lld:pubmed |
| entrez-gene:12308 | entrezgene:pubmed | pubmed-article:9387877 | lld:entrezgene |
